Conversely, lower SLC44A2 expression was associated with better survival in pancreatic adenocarcinoma (PAAD), invasive breast cancer (BRCA), and adrenocortical carcinoma (ACC). Here, SLC44A2 is linked to adrenal cortex carcinoma.